FY2029 EPS Estimates for Disc Medicine Cut by HC Wainwright

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - HC Wainwright decreased their FY2029 earnings estimates for Disc Medicine in a research note issued to investors on Thursday, May 8th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $5.86 per share for the year, down from their previous forecast of $6.36. HC Wainwright has a "Buy" rating and a $118.00 price target on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03).

Several other equities research analysts also recently commented on the stock. Wedbush reaffirmed an "outperform" rating and issued a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Morgan Stanley reaffirmed an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. BMO Capital Markets increased their price target on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. TD Cowen started coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a "buy" rating for the company. Finally, Scotiabank raised their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Disc Medicine presently has an average rating of "Buy" and a consensus target price of $98.80.

Disc Medicine Stock Up 2.1%

NASDAQ IRON traded up $1.00 during trading hours on Monday, hitting $48.09. The company's stock had a trading volume of 442,342 shares, compared to its average volume of 349,983. The stock has a fifty day moving average of $46.10 and a 200 day moving average of $54.95. Disc Medicine has a twelve month low of $30.65 and a twelve month high of $68.73. The firm has a market capitalization of $1.66 billion, a P/E ratio of -12.08 and a beta of 0.77.

Insiders Place Their Bets

In other Disc Medicine news, CEO John D. Quisel sold 5,574 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $304,228.92. Following the transaction, the chief executive officer now directly owns 154,828 shares of the company's stock, valued at $8,450,512.24. This trade represents a 3.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $87,873.80. Following the completion of the transaction, the chief operating officer now directly owns 40,555 shares in the company, valued at approximately $2,213,491.90. This represents a 3.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 356,290 shares of company stock worth $19,336,901 in the last quarter. 4.24% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds have recently bought and sold shares of the company. Amalgamated Bank increased its holdings in Disc Medicine by 38.6% in the 1st quarter. Amalgamated Bank now owns 787 shares of the company's stock valued at $39,000 after buying an additional 219 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after purchasing an additional 266 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Disc Medicine by 8.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock valued at $308,000 after purchasing an additional 396 shares during the last quarter. Sterling Capital Management LLC grew its holdings in shares of Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after purchasing an additional 503 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in shares of Disc Medicine by 12.5% during the 1st quarter. Arizona State Retirement System now owns 5,315 shares of the company's stock valued at $264,000 after purchasing an additional 590 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.